Evommune Inc (EVMN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2024 | |
| Cash Flows From Operating Activities | |
| Net Income | -46,082 |
| Depreciation Amortization | 927 |
| Accounts payable and accrued liabilities | 3,652 |
| Other Working Capital | 5,618 |
| Other Operating Activity | -3,798 |
| Operating Cash Flow | $-39,683 |
| Cash Flows From Investing Activities | |
| Change In Deposits | 29,175 |
| PPE Investments | -88 |
| Investing Cash Flow | $29,087 |
| Cash Flows From Financing Activities | |
| Debt Repayment | -284 |
| Common Stock Issued | 2 |
| Financing Cash Flow | $-282 |
| Beginning Cash Position | 29,232 |
| End Cash Position | 18,354 |
| Net Cash Flow | $-10,878 |
| Free Cash Flow | |
| Operating Cash Flow | -39,683 |
| Capital Expenditure | -88 |
| Free Cash Flow | -39,771 |